Follow
Christoph Correll; Christoph U Correll
Christoph Correll; Christoph U Correll
Professor of Psychiatry and Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Hempstead, NY USA; Professor of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany; Investigator, Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research Manhasset, NY, USA
Verified email at northwell.edu - Homepage
Title
Cited by
Cited by
Year
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
M De Hert, CU Correll, J Bobes, M Cetkovich-Bakmas, DAN Cohen, I Asai, ...
World psychiatry 10 (1), 52, 2011
27812011
Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies
M Solmi, J Radua, M Olivola, E Croce, L Soardo, G Salazar de Pablo, ...
Molecular psychiatry 27 (1), 281-295, 2022
21282022
How mental health care should change as a consequence of the COVID-19 pandemic
C Moreno, T Wykes, S Galderisi, M Nordentoft, N Crossley, N Jones, ...
The lancet psychiatry 7 (9), 813-824, 2020
18092020
Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large‐scale meta‐analysis of 3,211,768 patients …
CU Correll, M Solmi, N Veronese, B Bortolato, S Rosson, P Santonastaso, ...
World Psychiatry 16 (2), 163-180, 2017
15802017
Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review …
D Vancampfort, B Stubbs, AJ Mitchell, M De Hert, M Wampers, PB Ward, ...
World psychiatry 14 (3), 339-347, 2015
12482015
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
M De Hert, J Detraux, R Van Winkel, W Yu, CU Correll
Nature Reviews Endocrinology 8 (2), 114-126, 2012
12452012
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents
CU Correll, P Manu, V Olshanskiy, B Napolitano, JM Kane, AK Malhotra
Jama 302 (16), 1765-1773, 2009
12292009
The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness
J Firth, N Siddiqi, AI Koyanagi, D Siskind, S Rosenbaum, C Galletly, ...
The Lancet Psychiatry 6 (8), 675-712, 2019
12242019
Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level
M De Hert, DAN Cohen, J Bobes, M Cetkovich-Bakmas, S Leucht, ...
World psychiatry 10 (2), 138, 2011
10472011
Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology
OD Howes, R McCutcheon, O Agid, A De Bartolomeis, NJM Van Beveren, ...
American Journal of Psychiatry 174 (3), 216-229, 2017
9972017
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies
CU Correll, S Leucht, JM Kane
American Journal of psychiatry 161 (3), 414-425, 2004
9222004
Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder
CU Correll, J Detraux, J De Lepeleire, M De Hert
World psychiatry 14 (2), 119-136, 2015
8902015
Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE early treatment program
JM Kane, DG Robinson, NR Schooler, KT Mueser, DL Penn, ...
American Journal of Psychiatry 173 (4), 362-372, 2016
8842016
Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression
CU Correll, B Galling, A Pawar, A Krivko, C Bonetto, M Ruggeri, TJ Craig, ...
JAMA psychiatry 75 (6), 555-565, 2018
7782018
Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials
S Leucht, TRE Barnes, W Kissling, RR Engel, C Correll, JM Kane
American Journal of Psychiatry 160 (7), 1209-1222, 2003
7252003
Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta‐analysis
D Vancampfort, CU Correll, B Galling, M Probst, M De Hert, PB Ward, ...
World Psychiatry 15 (2), 166-174, 2016
7102016
Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment
CU Correll, NR Schooler
Neuropsychiatric disease and treatment, 519-534, 2020
7032020
EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA …
B Stubbs, D Vancampfort, M Hallgren, J Firth, N Veronese, M Solmi, ...
European Psychiatry 54, 124-144, 2018
6092018
National trends in the mental health care of children, adolescents, and adults by office-based physicians
M Olfson, C Blanco, S Wang, G Laje, CU Correll
JAMA psychiatry 71 (1), 81-90, 2014
5812014
Non‐adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies
JM Kane, T Kishimoto, CU Correll
World psychiatry 12 (3), 216-226, 2013
5622013
The system can't perform the operation now. Try again later.
Articles 1–20